Wire · opportunities
Aurion Biotech Completes Enrollment in Pivotal ASTRA Phase 3 Study, Advancing ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 23 September 2026 · Fusion42 review
Aurion Biotech has completed enrollment in its pivotal Phase 3 ASTRA study for AURN001, a potential first-in-class regenerative cell therapy for corneal edema secondary to corneal endothelial dysfunction. This single-administration therapy aims to restore vision by regenerating corneal clarity and addresses limitations of current surgical treatments and donor tissue scarcity.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 23 Sep 2026 and 25 Sep 2026.
◆ ◆ The Wire takeaway
Aurion's milestone in patient enrollment moves regenerative corneal therapy closer to market approval, offering you a chance to rethink treatments relying on donor tissue scarcity. Companies in eye care can now prepare for a shift from surgical complexity to simpler cellular therapies.
◆ Coverage
2 sources · first reported 23 Sep 2026 · latest 25 Sep 2026
◆ Related on Wire
◆ Topics